Gilead said Tuesday that it will soon begin Phase 3 testing for a drug it believes could prevent HIV infection with just a single shot
Two prominent gene-editing startups, Chroma Medicine and Nvelop Therapeutics, said Wednesday they will merge, forming a new company called nChroma Bio. The merger will combine
Terry Pirovolakis receives roughly 5 to 10 messages a week from strangers. Sometimes, his inbox fills overnight with emails from China. Sometimes, he’ll end a
Five years ago, a small startup led by biotech veteran Michael Gilman announced progress against a cancer gene that had bedeviled drug developers for 40
Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based drugs to treat rare diseases
Alector Therapeutics said Monday that its Phase 2 trial for an experimental Alzheimer’s antibody failed, dealing a blow to what had been one of the
Novartis said Thursday it purchased gene therapy startup Kate Therapeutics for up to $1.1 billion in upfront payments and milestones. It’s a rare buyout for
Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day. Repeatedly, the company has announced positive
Michelle Monje-Deisseroth says she first treated patients with “the worst imaginable childhood brain tumor” as a medical student about 20 years ago. Diffuse intrinsic pontine
For several years, a rivalry has been brewing between two high-profile gene-editing companies. On one hand is Prime Medicine, built on prime editing, a technology